- Home
- OUSTZ vs PSTV Comparison
OUSTZ vs PSTV Comparison
Compare OUSTZ & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUSTZ
- PSTV
- Stock Information
- Founded
- OUSTZ N/A
- PSTV 1996
- Country
- OUSTZ United States
- PSTV United States
- Employees
- OUSTZ 290
- PSTV N/A
- Industry
- OUSTZ Industrial Machinery/Components
- PSTV Medical/Dental Instruments
- Sector
- OUSTZ Industrials
- PSTV Health Care
- Exchange
- OUSTZ Nasdaq
- PSTV Nasdaq
- Market Cap
- OUSTZ N/A
- PSTV 6.3M
- IPO Year
- OUSTZ N/A
- PSTV N/A
- Fundamental
- Price
- OUSTZ $0.08
- PSTV $1.26
- Analyst Decision
- OUSTZ
- PSTV Strong Buy
- Analyst Count
- OUSTZ 0
- PSTV 2
- Target Price
- OUSTZ N/A
- PSTV $13.50
- AVG Volume (30 Days)
- OUSTZ N/A
- PSTV 21.3K
- Earning Date
- OUSTZ N/A
- PSTV 03-04-2025
- Dividend Yield
- OUSTZ N/A
- PSTV N/A
- EPS Growth
- OUSTZ N/A
- PSTV N/A
- EPS
- OUSTZ N/A
- PSTV N/A
- Revenue
- OUSTZ N/A
- PSTV $5,725,000.00
- Revenue This Year
- OUSTZ N/A
- PSTV $32.12
- Revenue Next Year
- OUSTZ N/A
- PSTV N/A
- P/E Ratio
- OUSTZ N/A
- PSTV N/A
- Revenue Growth
- OUSTZ N/A
- PSTV 52.63
- 52 Week Low
- OUSTZ N/A
- PSTV $0.93
- 52 Week High
- OUSTZ N/A
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- OUSTZ N/A
- PSTV 55.29
- Support Level
- OUSTZ N/A
- PSTV $1.19
- Resistance Level
- OUSTZ N/A
- PSTV $1.26
- Average True Range (ATR)
- OUSTZ 0.00
- PSTV 0.04
- MACD
- OUSTZ 0.00
- PSTV 0.01
- Stochastic Oscillator
- OUSTZ 0.00
- PSTV 83.27
About OUSTZ Ouster Inc. Warrants
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).